In the largest and most conclusive study of its kind, researchers have analysed blood samples to create a novel and non-invasive way of helping to diagnose Alzheimer’s disease and distinguish between different types of neurodegenerative disorders.
Following this breakthrough discovery, Alzheimer’s sufferers may now have an additional test to improve the accuracy of diagnosis in order to better tailor appropriate treatment.
The research also offers a valuable opportunity to monitor the progression of the disease.
The international study in the Proceedings of the National Academy of Sciences USA used sensor-based technology with a diamond core to analyse approximately 550 blood samples.
By passing light through the diamond and observing its interactions with the blood plasma, researchers were able to identify specific chemical bonds within the blood. This biochemical data was used to compare blood samples from cases of Alzheimer’s disease and other neurodegenerative diseases with those from healthy controls.
The ground-breaking scientific investigation was carried out by researchers at Lancaster University, the University of Central Lancashire (UCLan), the University of Manchester and the Federal University of Rio Grande do Norte, Brazil.
Professor David Allsop from Lancaster University has been collaborating for many years withProfessor David Mann from the University of Manchester in searching for diagnostic markers for neurodegenerative disease in blood plasma.
They provided all of the plasma samples for the study, along with supporting clinical and genetic information, and expertise in Alzheimer’s and other neurodegenerative conditions.
Professor Allsop said: “A particularly exciting aspect of the study was the ability to distinguish accurately between Alzheimer’s disease and Lewy body dementia, which are conditions that both result in dementia and can be difficult to separate from each other based on clinical information and symptoms. By reduction of misdiagnosed cases and administration of appropriate treatment, many people could benefit from this type of blood test in the future.”
Alzheimer’s diagnosis currently involves careful medical evaluation including clinical history, memory testing and brain scans, yet the only conclusive diagnosis is determined by post-mortem examination. This new blood test offers a non-invasive, more accurate and relatively cost-effective method of diagnosis, which will ensure the correct management of the condition.
Professor Francis Martin, principal investigator of the study and Biosciences theme lead at UCLan, said: “We have an aging population, meaning that the incidence and prevalence of Alzheimer’s is increasing, as is the need for accurate diagnosis. The ability to identify different neurodegenerative diseases through the analysis of blood offers a faster and accurate way of establishing the most effective treatment plan as well as disease monitoring.”
This new approach could also offer potential for carrying out tests to identify and monitor early signs of mild cognitive impairment, meaning that the onset of Alzheimer’s and other types of neurodegenerative diseases could be detected early and intervention measures could be put in place earlier to slow the progress of these diseases.
Professor Martin added: “For those suffering with Alzheimer’s disease, the damage is already well advanced once conventionally diagnosed, but this new method offers a potentially effective early screening tool when patients are only demonstrating signs of mild cognitive impairment. This is a potentially significant breakthrough for the prevention of different debilitating and chronic neurological diseases.”
The Latest on: Alzheimer’s
- Study shows intricate association of aluminum in the neuropathology of familial Alzheimer's diseaseon April 10, 2021 at 10:25 pm
This study builds upon two earlier published studies (Mold et al., 2020, Journal of Alzheimer's Disease Reports) from the same group. The new data, also published in the Journal of Alzheimer's Disease ...
- Your Alzheimer's Risk Increases Dangerously By Doing This, Say Doctorson April 10, 2021 at 4:45 am
You can reduce your risk of Alzheimer's and dementia through simple lifestyle tweaks. Read on to discover healthy habits.
- Disability Claims For People with Alzheimer's Diseaseon April 9, 2021 at 1:22 pm
Today, more than 5 million Americans are living with Alzheimer's disease. Since the onset of Alzheimer's can occur in people before they retire, it may strike during an individual's working years ...
- Aluminum is intricately associated with the neuropathology of familial Alzheimer's diseaseon April 9, 2021 at 8:48 am
A new study builds upon two earlier published studies (Mold et al., 2020, Journal of Alzheimer's Disease Reports) from the same group. The new data, also published in the Journal of Alzheimer's ...
- Leaking calcium in neurons an early sign of Alzheimer’s pathologyon April 9, 2021 at 7:23 am
New findings about early pathological changes in the brain may provide strategies to slow or prevent the progression of Alzheimer’s, Yale researchers report.
- PLD3 gene contributes to risk of Alzheimer's diseaseon April 8, 2021 at 11:02 am
A rare and controversial mutation in the phospholipase D3 (PLD3) protein—previously linked to Alzheimer's disease—interferes with PLD3's vital recycling function inside neurons. Matthew Schrag of ...
- Fifth Annual Aces for Alzheimer's Trivia Fundraiser Goes Virtual, Sets High Goalson April 8, 2021 at 5:00 am
LARCHMONT, NY / ACCESSWIRE / April 8, 2021 / Aces for Alzheimer's has moved its fundraising efforts online with a Virtual Team Trivia Night on Sunday, April 18, 2021. The event runs from 5:30 to 7 PM ...
- Alzheimer's stole his wife's memories. Then COVID stole their goodbye.on April 8, 2021 at 2:03 am
She kept repeating the same thing she’d just said, not remembering she’d already said it. The diagnosis of Alzheimer’s disease and the slow dissolve of her mind that followed is another sad ...
- Physiological clearance of amyloid-beta by the kidney and its therapeutic potential for Alzheimer’s diseaseon April 7, 2021 at 9:25 pm
Alzheimer’s Association . 2020 Alzheimer’s disease facts and figures. Alzheimers Dement. 2020. Braak H, Del, Trecidi K. Neuroanatomy and pathology of sporadic Alzheimer’s disease. Adv Anat Embryol ...
- Alzheimer’s Disease Treatment Market Value Predicted To Reach US$ 5,647.5 Million By 2027: Acumen Research And Consultingon April 7, 2021 at 7:13 am
Acumen Research and Consulting, a global provider of market research studies, in a recently published report titled “Alzheimer’s Disease Treatment Market– Global Industry Analysis ...
via Google News and Bing News